INmune Bio Inc.

INmune Bio completed a $19 million registered direct offering on June 27, 2025, extending its operational runway through 2026 to support its lead Alzheimer's therapy XPro™.

INmune Bio's XPro™ (XPro1595, pegipanermin) significantly reduced amyloid formation and improved brain function in transgenic mice following traumatic brain injury.

INmune Bio has partnered with Cell and Gene Therapy Catapult to establish commercial-scale manufacturing for CORDStrom, a promising therapy for recessive dystrophic epidermolysis bullosa that showed positive results in Phase 2 trials.

INmune Bio presented baseline demographics from its MINDFuL Phase II trial showing 208 patients with early Alzheimer's disease and confirmed biomarkers of inflammation, with 69.2% being APOE ε4 carriers.

INmune Bio's Natural Killer cell therapy INKmune™ demonstrates strong safety profile in Phase I trial for metastatic castration-resistant prostate cancer, enabling progression to Phase II high-dose cohort.

INmune Bio announces plans to submit Biologics License Application (BLA) to FDA for CORDStrom following successful Type C meeting.

INmune Bio's CaRe PC trial, evaluating INKmune in metastatic castration-resistant prostate cancer (mCRPC), has expanded to the West Los Angeles VA Medical Center.

OmniScience and INmune Bio are collaborating to enhance a Phase 2 Alzheimer's trial using OmniScience's Vivo, an AI-powered platform for real-time clinical data analysis.

INmune Bio has finalized enrollment of 208 patients in its Phase 2 AD02 trial for early Alzheimer's disease, focusing on individuals with biomarkers indicating neuroinflammation.

INmune Bio has finalized patient randomization for its Phase 2 trial (AD02) in early Alzheimer's disease, enrolling a total of 208 patients.